Found 96 results in Expert Content

Industry experts as they delve into the driving forces that have created the recent surge in treatments for oncology and rare disease.

During the webinar, viewers will gain valuable insights through a series of case studies demonstrating how mathematical and computerized models were utilized to improve scale-up and efficiency in oral solid dose manufacturing.

Learn how to accelerate and de-risk clinical-stage drug programs by understanding phase-appropriate strategies that can give your molecule the best chance for success!

An advanced development offering that integrates formulation expertise with on-demand Phase 1 clinical manufacturing, adaptive clinical testing and regulatory support, to help achieve flexible and efficient First-in-Human studies and expedited development.

Summary: In this webinar, industrial and academic experts will share insights into faster drug product manufacturing in a large-scale setting, discuss emerging trends in OSD manufacturing and share strategies to ensure that quality is built into manufacturing processes.

Learn how a biopharmaceutical company partnered with Catalent to develop and manufacture a commercially-viable, patient-friendly, stable tablet for a program intended to treat a disease that has unmet medical need.

This article discusses a systematic approach to ensure tech transfers meet scheduled timelines.

This executive summary provides expert insight on overcoming manufacturing challenges associated with expedited development programs.

Summary: In this webinar, experts provide an overview of the latest trends in manufacturing of oral solid dosage form and discuss key considerations of transitioning an early-stage project to late-stage as well as technology transfer.

Summary: A growing number of drug launches have faltered at the final hour because manufacturing processes weren’t up to FDA standards. This webinar explores how drug developers can properly monitor quality throughout the clinical production process and fix any issues that arise—before the FDA brings out the red flags.